WallStSmart

CVS Health Corp (CVS)vsGE HealthCare Technologies Inc. (GEHC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

CVS Health Corp generates 1806% more annual revenue ($399.83B vs $20.98B). GEHC leads profitability with a 9.1% profit margin vs 0.4%. CVS appears more attractively valued with a PEG of 0.24. CVS earns a higher WallStSmart Score of 65/100 (C+).

CVS

Buy

65

out of 100

Grade: C+

Growth: 7.3Profit: 4.0Value: 7.3Quality: 5.0
Piotroski: 4/9Altman Z: 2.11

GEHC

Buy

57

out of 100

Grade: C

Growth: 4.0Profit: 6.5Value: 7.3Quality: 4.3
Piotroski: 2/9Altman Z: 1.34
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CVSUndervalued (+77.4%)

Margin of Safety

+77.4%

Fair Value

$340.13

Current Price

$86.86

$253.27 discount

UndervaluedFair: $340.13Overvalued
GEHCUndervalued (+43.4%)

Margin of Safety

+43.4%

Fair Value

$139.96

Current Price

$61.04

$78.92 discount

UndervaluedFair: $139.96Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CVS5 strengths · Avg: 9.4/10
PEG RatioValuation
0.2410/10

Growing faster than its price suggests

Price/BookValuation
1.5x10/10

Reasonable price relative to book value

EPS GrowthGrowth
76.6%10/10

Earnings expanding 76.6% YoY

Market CapQuality
$105.21B9/10

Large-cap with strong market position

Free Cash FlowQuality
$2.61B8/10

Generating 2.6B in free cash flow

GEHC2 strengths · Avg: 8.0/10
P/E RatioValuation
14.6x8/10

Attractively priced relative to earnings

Price/BookValuation
2.7x8/10

Reasonable price relative to book value

Areas to Watch

CVS4 concerns · Avg: 3.0/10
Return on EquityProfitability
2.3%3/10

ROE of 2.3% — below average capital efficiency

Profit MarginProfitability
0.4%3/10

0.4% margin — thin

Operating MarginProfitability
1.6%3/10

Operating margin of 1.6%

Debt/EquityHealth
1.243/10

Elevated debt levels

GEHC4 concerns · Avg: 2.8/10
PEG RatioValuation
1.724/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-30.9%2/10

Earnings declined 30.9%

Altman Z-ScoreHealth
1.342/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : CVS

The strongest argument for CVS centers on PEG Ratio, Price/Book, EPS Growth. PEG of 0.24 suggests the stock is reasonably priced for its growth.

Bull Case : GEHC

The strongest argument for GEHC centers on P/E Ratio, Price/Book.

Bear Case : CVS

The primary concerns for CVS are Return on Equity, Profit Margin, Operating Margin. A P/E of 59.1x leaves little room for execution misses. Thin 0.4% margins leave little buffer for downturns.

Bear Case : GEHC

The primary concerns for GEHC are PEG Ratio, Piotroski F-Score, EPS Growth.

Key Dynamics to Monitor

GEHC carries more volatility with a beta of 1.30 — expect wider price swings.

CVS is growing revenue faster at 8.4% — sustainability is the question.

CVS generates stronger free cash flow (2.6B), providing more financial flexibility.

Monitor HEALTHCARE PLANS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

CVS scores higher overall (65/100 vs 57/100). GEHC offers better value entry with a 43.4% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

CVS Health Corp

HEALTHCARE · HEALTHCARE PLANS · USA

CVS Health (previously CVS Corporation and CVS Caremark Corporation) is an American healthcare company that owns CVS Pharmacy, a retail pharmacy chain; CVS Caremark, a pharmacy benefits manager; Aetna, a health insurance provider, among many other brands. The company's headquarters is in Woonsocket, Rhode Island.

Visit Website →

GE HealthCare Technologies Inc.

HEALTHCARE · MEDICAL DEVICES · USA

GE HealthCare Technologies Inc. provides medical technology, pharmaceutical diagnostics, and digital solutions in the United States. The company is headquartered in Chicago, Illinois.

Want to dig deeper into these stocks?